Mechanisms implicated in the growth regulatory effects of vitamin D compounds in breast cancer cells.

摘要: The active metabolite of vitamin D31,25-dihydroxyvitamin D3 (1,25(OH)2D3), has been recognized for over 2 decades as a modulator cell proliferation and differentiation in many types, including breast cancer. However, any potential anti-tumour properties displayed by 1,25(OH)2D3 are limited the tendency to cause hypercalcaemia when administered at high doses. Because this, synthetic D analogues have developed that retain effects seen with but which reduced calcaemic activity. it is still unclear how its act within cancer cells elicit on cellular differentiation. In this chapter we review advances made trying answer question. It found so far an effect expression certain cycle regulators way can bring about G1 arrest. Evidence also emerged compounds affect growth-promoting pathways initiated two important factors involved promotion; namely insulin-like growth factor I (IGF-I) oestrogen-receptor (ER) pathways. Vitamin implicated promotion apoptosis evidence suggests may potentiate responsiveness conventional cytotoxic agents. Although much remains be learned associated underlying mechanisms, ongoing research new class treatment prevention.